Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis (UC), affect more than 1 million people in the United States. Lysophosphatidic acid (LPA) is known to be a regulator of inflammation as well as governor of vascular structure function, and has been suggested to to be a regulator of lymphatic lineage and patterning. LPA levels are controlled both by the synthesis and catabolism of LPA by several enzymes especially lipid phosphate phosphatase-3 (LPP3). We previously reported remarkable intestinal blood and especially lymphatic vascularization in the 3% dextran sodium sulfate murine model of ulcerative colitis, which may be either adaptive or injurious depending on the phase of the model.